Anti-cancer activity of dose-fractioned mPE +/− bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients

BACKGROUND: Results from the BEVA2007 trial, suggest that the metronomic chemotherapy regimen with dose-fractioned cisplatin and oral etoposide (mPE) +/− bevacizumab, a monoclonal antibody to the vascular endothelial growth factor (VEGF), shows anti-angiogenic and immunological effects and is a safe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Thorac Dis
Main Authors: Pastina, Pierpaolo, Nardone, Valerio, Croci, Stefania, Battaglia, Giuseppe, Vanni, Francesca, Bellan, Cristiana, Barbarino, Marcella, Ricci, Veronica, Costantini, Susan, Capone, Francesca, Botta, Cirino, Zarone, Mayra Rachele, Misso, Gabriella, Boccellino, Mariarosaria, Caraglia, Michele, Giordano, Antonio, Paladini, Piero, Tassone, Pierfrancesco, Tagliaferri, Pierosandro, Cusi, Maria Grazia, Pirtoli, Luigi, Correale, Pierpaolo
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2017
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5708460/
https://ncbi.nlm.nih.gov/pubmed/29221287
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2017.08.68
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados